gretel
24 Aug 2017
RNS : earnings-enhancing acquisition Another excellent and nicely earnings-enhancing acquisition. Looks like a cheap price too given £1.2m maximum consideration for a likely £200,000 PBT given lower sales and marketing investment costs after 2016:[link] recurring income and overseas sales are also encouraging, and I'm assuming there's potential for integration/sales synergies with SDI's existing product portfolio as a "complementary businesses" with "areas within ATC with potential for growth".
gretel
03 Aug 2017
New product introduction Atik introduce an impressive-looking new camera - and with an "overwhelming response" for Beta testers and a "huge number of applicants":[link] New Atik Horizon CMOS CameraJo on July 27th, 2017 Since announcing development of our first CMOS camera in May, we’ve been busy getting things ready for release. We’ve locked down our case design, boosted our cooling and now have our full set of provisional specifications. So, without further ado, let us introduce you to the Atik Horizon........Last week we put out a call for BETA testers for the new Atik Horizon. With such an overwhelming response, we are currently not accepting any new applications for BETA Testers. The initial production run is extremely limited, and we’ve had a huge number of applicants already. If you’ve applied, we like to say a huge thank you for your interest and will get back to you about next steps in due course. We anticipate the full release to follow in early October....."
gretel
02 Aug 2017
Exciting news re ProReveal It's now been adopted by 10 NHS Trusts - and this should grow substantially over the next year, as full compliance with new DOH guidelines is expected by 2018. Plus it's already started to sell in the USA, with distributors appointed for the Asia-Pacific region:[link] of the ProReveal Technology to comply with the Protein detection requirements of HTM01
1Published on July 25, 2017Matthew PeskettPeskett Solutions Ltd I am pleased to announce that the ProReveal has been adopted to date by 10 NHS Trusts in the UK to comply with the protein detection requirements of the updated HTM011. The ProReveal is not only helping with their compliance. It is also giving them technology, that is helping with their wash process optimisation.''This ProReveal NHS adoption is also now featured on SDI's company web site:[link] 2nd August, 2017HTM011We are pleased to announce that the ProReveal has been adopted to date by 10 NHS Trusts in the UK to comply with the protein detection requirements of the updated HTM011. The ProReveal is not only helping with their compliance - it is also giving them technology, that is helping with their wash process optimisation.Link to original article"
claude reins
31 Jul 2017
Re: Great new article about SDI PS Im a holder so intend to hold though have quite a large holding forf me so cannot say strong buy on this 'evidence' alone.
claude reins
31 Jul 2017
Re: Great new article about SDI Thnaks for that. Very encouraging to get supportive recommendations.
gretel
31 Jul 2017
Great new article about SDI [link] P/E of 13 falling to 11 - with around 10% of the m/cap supported by the cash pile - is pretty decent value anyway. But Proreveal's progress adds a transformational leg to the business given not only initial sales, but more importantly the high margin subsequent recurring income.Particularly if it takes off in the USA following the sales and trials over there, together with potential from the new European and Asian distributors.Encouraging to hear that any new acquisition won't require dilution too. Hopefully there's another one on its way soon.
claude reins
27 Jul 2017
Re: Good results, bullish outlook today Any thoughts on why this continues to show a decline in SP and a widening ask to bid ratio? You were quite bullish yesterday. Trades not insignificant, and already 2 x 3-montly daily average? Only your and SCSW continuing support keeps me going in these troubled times!
gretel
26 Jul 2017
Good results, bullish outlook today Good results this morning, plus in particular
1) A very bullish outlook:"The Board is confident that SDI is now in an excellent position for profitable growth through increased revenue and the potential for additional acquisitions in 2017/18. The Board views the current financial year very positively"(2) Proreveal seems to be making very good progress, being "trialled by NHS hospitals across the UK and the sale in 2017 of eight systems".I calculate 1.74p historic adjusted EPS based on £1.3m PBT, a £75k tax charge and 70.97m shares in issue, which is bang on expectations.[link] wonder if forecasts for this year of 1.9p EPS will now be increased, as they were left unchanged following the Astles acquisition by Finncap.
biswell2
15 Jul 2017
SDI Chart Moving Averages Rising On friday the 100 day moving average hit 24.8pThe 100 day moving average should cross the 50 day moving average next week at 25p as interest in SDI seems to be rekindled towards results day.One would imagine if earnings come in as forecast , 1.7p a share , the recent high of 34p might get a visit once more.Especially if the 2018 forecast of 1.9p a share is restated as a full 12 months input from the recent Astles acquisition kicks in during that year with perhaps news of another acquisition to come soon. FinnCap has a ridiculous 20p on this share , after previously having 29p on it which they reduced.Does that company look at moving averages ?Or take note of the Astles acquisition , the biggest and best performer bought to date at around 5 year CAGR 19% ?They have not reacted to the big impact that Astles is going to have on SDI with their outdated 20p price , which the market clearly has taken no notice of whatsoever .One would now imagine that the next acquisition will be done by raising cash at over 20pShouldn't prove too difficult when the SP is around the 30p plus mark.
IOMINVESTCOM
14 Jul 2017
Showing some signs of life?? Showing some strength over last couple of days.....[link]
gretel
02 Jun 2017
Good news today [link] 2nd June 2017Leading German University opts for second Syngene imaging systemCambridge, UK: Syngene, a world-leading manufacturer of image analysis solutions, today announced its G:BOX Chemi XX6 multi-application imager is being utilised by scientists at a top University in Germany to speed up analysis of genes and proteins associated with neurodegenerative conditions.Researchers at the German University are using a G:BOX Chemi XX6 multi-application imager to rapidly detect genotypic changes on fluorescent DNA gels and accurately analyse proteins expressed in human cell lines and animal models of neurodegenerative diseases. To detect changes in protein expression, the scientists are utilising ECL-based chemiluminescent Western blots. This data is providing information which could help develop safer, more effective immunotherapies to treat incurable neurodegenerative conditions.The Laboratory Manager at the German University stated: “We have had an older Syngene gel doc system in our lab for many years, which we use for visualising DNA on our genotyping gels. We are very happy with its performance but this system cannot analyse chemiluminescent Western blots. This meant we were spending many hours developing X-ray film of our Westerns and it was difficult, as well as time consuming trying to quantify protein amounts.”The Laboratory Manager continued: “We upgraded to the newer G:BOX Chemi XX6 in 2016 because we like how quick and easy the Syngene imaging software is to use. The system is now being used daily by 10 researchers and we’re analysing our Western blot results much faster than when we were using X-ray film. The other benefits are that we have confidence in the protein quantification results we’re obtaining and we can store images which we can use directly in publications so we’re very happy with our G:BOX Chemi XX6 system.”To find out about the exciting applications a G:BOX Chemi XX6 imager can perform, scientists can click this link: www.syngene.com/g-box-chemi-xx6/“We’re proud to hear that this major German University has installed a second Syngene imaging system to accelerate their research in neurodegenerative diseases,” states Dr Martin Biggs, Sales Manager at Syngene. “Their choice of a G:BOX Chemi XX6 for use by so many different researchers demonstrates how robust and easy to use this technology is for producing accurate protein expression and genotyping results.”
claude reins
26 May 2017
Re: Positive year end trading update Hi there again, Gretel. Surprised to see the shares fall 11%? They had a good write up in SCSW a couple of months ago and were bought by them for their portfolio. I thought after reading Paul Scott on Stockopedia this morning that they seem a fair bet so have invested near the day's end at a reasonable price. SCSW have said they see them as another Judges Scientific which did very well for them in an earlier potfolio, and they still hold in high regard even at the current price. They think SDI could be a multi bagger. Let's hope so for all of us.
gretel
26 May 2017
Positive year end trading update Encouraging (if brief!). Good to see the Astles acquisition performing to expectations - and in the comment about replicating the business model there's a strong hint that more acquisitions are on the horizon.
gretel
16 May 2017
Another new product [link] 15th May 2017Lauch of new integrated ProtoCOL 3 and UNISTAT Bioassay SofwareCambridge, UK: Synbiosis, a long-established, expert manufacturer of automated microbiological systems, is delighted to announce that UNISTAT bioassay analysis software has been integrated for use with ProtoCOL 3 colony counting and inhibition zone measuring system. UNISTAT’s Analysis of Bioassays module, available from Synbiosis, will allow scientists a quick, easy method of analysing their ProtoCOL 3 data to generate accurate antibiotic and vaccine potency results.With just one click of the ProtoCOL 3 system, microbiologists can export inhibition zone measurement and colony count data directly to UNISTAT. The UNISTAT software supports calculations including Parallel Line Method and Slope Ratio Method, to produce potencies with confidence limits and analysis of variance compliant with United States Pharmacopoeia and European Pharmacopoeia. The software also uses powerful tools to detect, omit or replace outliers.The UNISTAT software generates results in graphs and tables, thus saving time and preventing transcribing errors when transferring data. The module also offers tools to produce publication quality reports that will comply with 21 CFR Part 11 and Synbiosis can supply documentation to allow the UNISTAT software to be integrated with ProtoCOL 3 in a Good Manufacturing Practice (GMP) compliant environment. Dr Mehmet Toker, CEO of Unistat stated: “We wanted to develop an interface for UNISTAT software for direct use with the ProtoCOL 3 system because we have in the past collaborated with a top ten pharma to produce a specific custom solution so we know there is a demand for this type of application. There will be many major pharmaceutical and biotech companies that would benefit from the multi-purpose UNISTAT bioassay module and the interface we have developed working with Synbiosis and are delighted to be offering this excellent product via Synbiosis and its worldwide distribution network.”To find out more about the integrated UNISTAT bioassay analysis software for use with ProtoCOL 3, scientists can click this link: [link] bioassay software is a gold standard for statistical analysis in many pharma companies” explains Kate George, Senior Divisional Manager at Synbiosis. “UNISTAT experts have been working with our software developers for the past year to enable seamless data transfer into a format UNISTAT can process quickly and easily. Now we’re confident that the integrated ProtoCOL 3 and UNISTAT package we’re supplying is the perfect combination for antibiotic or vaccine manufacturing facilities that need to increase testing accuracy, as well as securely store their results for on-demand review by any major regulatory authority.”"
gretel
10 May 2017
More new product news [link] 9th May 2017New Syngene G:BOX imaging systems with HI-LED lightingCambridge, UK: Syngene, a world-leading manufacturer of image analysis solutions, is delighted to announce its latest options for its highly successful G:BOX automated multi-purpose gel and blot imaging systems are now available. Utilising high intensity, “HI-LED” lighting and updated image capture software, these flexible systems guarantee cost-effective imaging and faster workflow with a huge range of fluorescence gel and blot applications..........“Many scientists want to image multiplex gels but don’t currently because it takes too long using a CCD-based imaging system or they cannot afford the laser-based technology to view them rapidly”, explains Dr Martin Biggs, Senior Divisional Manager at Syngene. “We’re excited to introduce our new G:BOX HI-LED options because these systems are capable of such incredible performance that they are perfect for any lab looking to access a quick, affordable method of rapidly generating high quality, chemi, fluorescence, colorimetric and now stain-free gel images time after time.”
